Jump Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Jump Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$918K	Sell	94,000 -168,146	-64%	-$1.46M	0.01%	1228
2026 Q1	$1.46M	Buy	262,146 +208,330	+387%	+$1.59M	0.02%	781
2025 Q4	$396K	Buy	+53,816	New	+$329K	﹤0.01%	1420
2024 Q3	–	Sell	-1,787	Closed	-$23.3K	–	1896
2024 Q2	$23.3K	Buy	+1,787	New	+$29.6K	﹤0.01%	1703
2023 Q1	–	Sell	-3,898	Closed	-$199K	–	1822
2022 Q4	$199K	Buy	+3,898	New	+$270K	0.01%	1294
2022 Q3	–	Sell	-809	Closed	-$54K	–	1773
2022 Q2	$54K	Buy	+809	New	+$74.2K	﹤0.01%	1496
2022 Q1	–	Sell	-5,708	Closed	-$551K	–	1727
2021 Q4	$551K	Buy	+5,708	New	+$569K	0.03%	608
2021 Q3	–	Sell	-4,686	Closed	-$725K	–	1302
2021 Q2	$725K	Buy	4,686 +519	+12%	+$75.3K	0.07%	354
2021 Q1	$658K	Buy	+4,167	New	+$878K	0.06%	334

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jump Financial's KPTI Position: Q2 2026 in Review

Jump Financial reduced its Karyopharm Therapeutics (KPTI) stake by 64% in Q2 2026, selling an estimated $1.46M and leaving 94,000 shares worth $918K. The position accounts for 0.01% of the portfolio, ranked #1228.

Jump Financial first reported a position in KPTI in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.46M in Q1 2026. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Jump Financial held 94,000 shares of Karyopharm Therapeutics worth $918K as of Q2 2026.
Jump Financial sold 168,146 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.46M.
Karyopharm Therapeutics made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1228 holding.
Jump Financial first reported a position in Karyopharm Therapeutics in Q1 2021 and has held it in 9 quarters since.
Jump Financial's Karyopharm Therapeutics position peaked at $1.46M in Q1 2026.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.